Manaka Muneishi1, Ayaka Nakamura1, Katsumi Tachibana2, Junko Suemitsu2, Shinji Hasebe3, Kazuto Takeuchi4, Yoshihiro Yakushijin5,6. 1. Department of Clinical Oncology, Ehime University School of Medicine, Toon, Japan. 2. Medical Profession Division, Ehime University Hospital, Toon, Japan. 3. Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon, Japan. 4. Cancer Center, Ehime University Hospital, Toon, Japan. 5. Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon, Japan. yoshiyak@m.ehime-u.ac.jp. 6. Cancer Center, Ehime University Hospital, Toon, Japan. yoshiyak@m.ehime-u.ac.jp.
Abstract
BACKGROUND: Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL. METHODS: Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015. RESULTS: The median age of the patients was 60 years and the median follow-up was 58 months. A total of 25 cases with FL were treated with R monotherapy, and 28 cases were treated with R-CHOP as first-line treatment. The factors affecting the decision of physicians to use R or R-CHOP treatment were serum level of lactate dehydrogenase (LDH) and disease stage. The first-line treatment-associated survival did not show any statistical differences between R and R-CHOP. The average hospitalization and average of all medical costs during the first-line treatment were 4.1 days (R) versus 55.7 days (R-CHOP), and JPY 1,707,693 (USD 15,324) (R) versus JPY 2,136,117 (USD 19,170) (R-CHOP), respectively. CONCLUSION: R monotherapy for patients whose diseases show low tumor burden and who are not candidates for local treatment has benefits as a first-line treatment compared to R-CHOP, based on the patients' QOL and medical economics.
BACKGROUND:Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL. METHODS: Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015. RESULTS: The median age of the patients was 60 years and the median follow-up was 58 months. A total of 25 cases with FL were treated with R monotherapy, and 28 cases were treated with R-CHOP as first-line treatment. The factors affecting the decision of physicians to use R or R-CHOP treatment were serum level of lactate dehydrogenase (LDH) and disease stage. The first-line treatment-associated survival did not show any statistical differences between R and R-CHOP. The average hospitalization and average of all medical costs during the first-line treatment were 4.1 days (R) versus 55.7 days (R-CHOP), and JPY 1,707,693 (USD 15,324) (R) versus JPY 2,136,117 (USD 19,170) (R-CHOP), respectively. CONCLUSION: R monotherapy for patients whose diseases show low tumor burden and who are not candidates for local treatment has benefits as a first-line treatment compared to R-CHOP, based on the patients' QOL and medical economics.
Entities:
Keywords:
Follicular lymphoma; Medical economics; Rituximab
Authors: Marianne Brodtkorb; Ole Christian Lingjærde; Kanutte Huse; Gunhild Trøen; Marit Hystad; Vera I Hilden; June H Myklebust; Ellen Leich; Andreas Rosenwald; Jan Delabie; Harald Holte; Erlend B Smeland Journal: Blood Date: 2013-12-19 Impact factor: 22.113
Authors: Michel van Agthoven; Mark H H Kramer; Pieter Sonneveld; Klaas G van der Hem; Peter C Huijgens; Pierre W Wijermans; Hanneke C Kluin-Nelemans; M Ronald Schaafsma; Douwe H Biesma; Vera Mattijssen; Carin A Uyl-de Groot; Anton Hagenbeek Journal: Haematologica Date: 2005-10 Impact factor: 9.941
Authors: M Pinyol; F Cobo; S Bea; P Jares; I Nayach; P L Fernandez; E Montserrat; A Cardesa; E Campo Journal: Blood Date: 1998-04-15 Impact factor: 22.113
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113
Authors: Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke Journal: Blood Date: 2014-03-03 Impact factor: 22.113